AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by research analysts at Jefferies Group in a research report issued on Monday, May 14th, MarketBeat reports.
A number of other equities research analysts have also recently commented on the stock. Barclays set a GBX 6,500 ($87.21) target price on shares of AstraZeneca and gave the company a “buy” rating in a research report on Friday, May 11th. Shore Capital reiterated a “hold” rating on shares of AstraZeneca in a research report on Friday, May 11th. Credit Suisse Group restated an “outperform” rating on shares of AstraZeneca in a research report on Friday, May 4th. JPMorgan Chase restated an “overweight” rating on shares of AstraZeneca in a research report on Wednesday, April 25th. Finally, Goldman Sachs set a GBX 3,750 ($50.32) price objective on shares of AstraZeneca and gave the stock a “sell” rating in a research report on Tuesday, April 24th. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of GBX 5,253.43 ($70.49).
Shares of AstraZeneca traded up GBX 37 ($0.50), reaching GBX 5,454 ($73.18), during mid-day trading on Monday, according to MarketBeat. The company’s stock had a trading volume of 2,149,253 shares, compared to its average volume of 2,310,000. AstraZeneca has a 1-year low of GBX 4,260 ($57.16) and a 1-year high of GBX 5,520 ($74.06).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.